Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma of the Prostate × capivasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 20 Prostatic Neoplasms 7 Triple Negative Breast Neoplasms 6 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Melanoma 3 Lymphoma 3 Lung Neoplasms 3 Hematologic Neoplasms 3 Endometrial Neoplasms 3 Uterine Cervical Neoplasms 2 Recurrence 2 Neoplasms 2 Multiple Myeloma 2 Locally Advanced (Inoperable) or Metastatic Breast Cancer 2 Leukemia 2 Healthy Participants 2 Disease Progression 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumour 1 Rectal Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1

Interventions

enzalutamide 2 sipuleucel-T 1 pazopanib 1 capivasertib 1 Watchful Waiting 1 STA 9090 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy 1 Radiosurgery 1 Dutasteride 1 Androgen Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02525068 2018-08-08

RE-AKT

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Adenocarcinoma of the Prostate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡